AGP Executive Report
Last update: 8 hours agoDiabetes Tech in Primary Care: The ADA’s 2026 Scientific Sessions highlighted the CONNECT randomized trial showing Dexcom G7 CGM use in adults with type 2 diabetes not on insulin cut A1C by 1.6% over 26 weeks—an ADA “highest level A” support signal that could reshape routine care. Obesity Drug Pipeline: At the same meeting, Eli Lilly’s retatrutide posted phase 3 results in both obesity/overweight (TRIUMPH-1) and early type 2 diabetes (TRANSCEND-T2D-1), with major weight loss and A1C improvements reported. Safety Watch on Retatrutide: New safety details shared alongside the data noted arrhythmias and major cardiovascular complications in a small share of retatrutide-treated participants versus none on placebo. Heart Pacing, Noninvasively: Researchers described an ultrasound-based “sonogenetics” pacemaker concept aimed at stabilizing heart activity without implanted devices. Personalized Osteoarthritis Care: A review says osteoarthritis is increasingly diagnosed in people as young as 30 and should be treated as a spectrum of different underlying drivers, not one uniform condition. Disability Support Policy: Kansas’ Money Follows the Person program appears to be facing renewed uncertainty after earlier reductions, raising concerns for people transitioning to independent living. Public Health & Environment: An EPA proposal would roll back coal ash protections, critics say it could worsen contamination and health risks for communities.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
